Adjunctive Use of Apyrase to Fibrinolytic Therapy

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43HL095169-01A1
Agency Tracking Number: HL095169
Amount: $226,120.00
Phase: Phase I
Program: SBIR
Awards Year: 2009
Solitcitation Year: 2009
Solitcitation Topic Code: N/A
Solitcitation Number: PHS2009-2
Small Business Information
APT THERAPEUTICS, INC.
APT THERAPEUTICS, INC., 893 NORTH WARSON ROAD, SAINT LOUIS, MO, 63141
Duns: 192266141
Hubzone Owned: Y
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 RIDONG CHEN
 (314) 608-6932
 RCHEN@NIDUSCENTER.COM
Business Contact
 RIDONG CHEN
Phone: (314) 812-8054
Email: rchen@niduscenter.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for treatment of acute myocardial infarction. This enzyme strongly inhibits platelet activation and aggregation with modest bleeding risk. Using a protein informatics approach, we have successfully engineered human apyrases which exhibit both antiplatelet and anti-inflammatory activities. With the Phase I grant support, we will determine whether optimized human apyrases, in combination with tPA, induce rapid and sustained coronary artery recanalization without increasing bleeding risk. PUBLIC HEALTH RELEVANCE: We will utilize a coronary thrombotic model in dogs to validate whether human apyrase more effectively improve coronary patency than clopidogrel without increasing bleeding risk.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government